LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Closed

SectorHealthcare

13.83 -0.29

Buy Sell

Overview

Share price change

24h

Current

Min

13.5

Max

13.99

Key metrics
By Trading Economics
Income	6.8M -12M
Sales	-1.5M 17M
Profit margin	-64.131
Employees	120
EBITDA	-16M -24M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+40.2% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	27M 449M
Previous open	14.12
Previous close	13.83

News Sentiment

By Acuity

75%

25%

318 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

5.04 / 5.44 Support & Resistance

ENANTA PHARMACEUTICALS INC Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 May 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 May 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 May 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 May 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 May 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 May 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 May 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 May 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 May 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 May 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 May 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 May 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 May 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 May 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 May 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 May 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

40.2% upside

12 Months Forecast

Average 19.67 USD 40.2%

High 20 USD

Low 19 USD

Based on 3 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ENANTA PHARMACEUTICALS INC - Dist in the past 3 months.

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

318 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.